Fierce Pharma
AUGUST 18, 2023
It was only last spring that Biogen started a | It was only last spring that Biogen started layoffs that eventually shrank the company’s headcount by nearly 900 people last year. Now, a fresh round of job cuts targeting 1,000 positions has kicked off at the struggling drugmaker. At the same time, Biogen is spending $7.3 billion to buy rare disease specialist Reata Pharmaceuticals.
MedCity News
AUGUST 18, 2023
Blue Shield of California is cutting many of its ties with CVS Caremark (though not all) and adding four additional partners for its prescription drug benefits. These partners include Mark Cuban Cost Plus Drug Company and Amazon Pharmacy. The changes are needed to disrupt the current broken system, said Salina Wong, senior director of clinical pharmacy programs at Blue Shield of California.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 18, 2023
Vexed by plummeting demand for their shots, COVID-19 vaccine producers are anxiously awaiting the fall inoculation season to get a glimpse of the post-pandemic market landscape, which includes a sh | Vexed by plummeting demand for their shots, COVID-19 vaccine producers are anxiously awaiting the fall inoculation season to get a glimpse of the post-pandemic market landscape.
MedCity News
AUGUST 18, 2023
We can begin to solve America’s nursing shortage in very short order with innovative educational and apprenticeship approaches that let young healthcare workers move up the skill ladder more quickly. Hospitals across the country are desperately struggling to find nurses. Traditional nursing programs take years of schooling with costs running to more than $100,000.
Fierce Pharma
AUGUST 18, 2023
Along with resolving site inspection issues that cost Regeneron a high-dose Eylea launch in June, the company has scored an FDA nod for Veopoz as the first treatment for the ultra-rare inherited im | Alongside a Friday approval for its ultra-rare disease medicine Veopoz, Regeneron now expects a high-dose Eyelea nod in the next few weeks after resolving inspection issues at third-party filler Catalent.
Pharmaceutical Technology
AUGUST 18, 2023
Bruker has entered into a definitive agreement to acquire functional cell biology company PhenomeX for a total equity value of $108m.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
AUGUST 18, 2023
The decision brings the first daily oral migraine prophylactic to Europe, with plans to rollout the treatment as soon as possible.
Fierce Pharma
AUGUST 18, 2023
Two years after Welireg's original approval in the rare von Hippel-Lindau (VHL) disease, Merck is looking to expand its drug's reach and turn it into a blockbuster. | The drug, which was originally approved in rare von Hippel-Lindau (VHL) disease, showed improvements in progression-free survival in a phase 3 trial comparing the med with Novartis' Afinitor.
MedCity News
AUGUST 18, 2023
Medtech funding reached its low point in the first quarter but will slowly pick back up over the rest of 2023, according to a new Pitchbook report. It noted that this year’s medtech funding total will not come close to the $19.7 billion the sector raised in 2021, and it might even come in below last year’s funding total of $13.5 billion.
Copyright Clearance Center
AUGUST 18, 2023
A stipulated permanent injunction prevents the Internet Archive from offering unauthorized copies of books to the global public.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
AUGUST 18, 2023
Astellas Pharma has announced that EMA has accepted the MAA from its subsidiary Iveric Bio for the review of ACP to treat GA.
European Pharmaceutical Review
AUGUST 18, 2023
The European Medicines Agency (EMA) has accepted for regulatory review the marketing authorisation application (MAA) for avacincaptad pegol (ACP) to treat geographic atrophy (GA). “This acceptance of our EU Marketing Authorisation Application is a key milestone in our global effort to help patients living with GA, a leading cause of blindness worldwide.
Pharmaceutical Technology
AUGUST 18, 2023
Depending on Phase III results, survodutide could soon enter the weight loss market, which is expected to reach $37.1bn by 2031.
PharmaTimes
AUGUST 18, 2023
Aquablation is a robotic method that uses a high-pressure saline solution to remove tissue - News - PharmaTimes
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Legacy MEDSearch
AUGUST 18, 2023
Highlighting a growing interest in body composition data, InBody is celebrating a long-anticipated milestone: 100 million tests taken globally on their body composition analyzers as of Friday, Aug. 4. “We’ve come a long way since InBody’s founding in 1996,” said Harry Yun, CEO of InBody USA. “The popularity of our tests is skyrocketing. Even the American Medical Association is changing their tune about BMI and recommending that body composition testing be used in clinical settings.
PharmaVoice
AUGUST 18, 2023
With Flagship and Pfizer’s newly announced partnership to find the next big blockbuster, we’re examining some of the VC fund’s biggest successes and failures to date.
PharmaTimes
AUGUST 18, 2023
The amalgamated company will focus on advancing neflamapimod for the treatment of dementia - News - PharmaTimes
Pharmaceutical Technology
AUGUST 18, 2023
Competitive intelligence is a vital tool of the research and analysis toolbox for firms wanting valuable data on their market, competitors and customers
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PharmaTech
AUGUST 18, 2023
Stuart Malcolm, head of Standards, Efficiency, and Automation at Veramed, speaks on how advancing technologies are shaping clinical trials.
Pharmaceutical Technology
AUGUST 18, 2023
Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.
PharmaTech
AUGUST 18, 2023
The assessment aims to determine whether valproate use in men could lead to neurodevelopmental disorders in their children.
Pharmaceutical Technology
AUGUST 18, 2023
Imugene's azercabtagene zarpreleucel (azer-cel) allo-CAR T cell therapy has shown a 58% ORR and 41% CR rate across all doses.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmacy Times
AUGUST 18, 2023
Previous studies have shown promising results with liver or kidney transplants in patients with HIV, but there was a lack of literature regarding heart transplants specifically.
Pharmaceutical Technology
AUGUST 18, 2023
Nuvectis Pharma has received US Food and Drug Administration (FDA) orphan drug designation for NXP800 to treat cholangiocarcinoma.
Pharmacy Times
AUGUST 18, 2023
Although the rate of people with probable insomnia who discussed their sleep habits with a physician was relatively high, the number of people who went on to seek actual treatment was low.
Pharmaceutical Technology
AUGUST 18, 2023
As restrictions on abortion drug mifepristone loom, doctors and patients are looking to off-label misoprostol as an alternative.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmacy Times
AUGUST 18, 2023
Based on results from a trial of repotrectinib in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, the FDA accepted the New Drug Application and set a Prescription Drug User Fee Act goal date of November 27, 2023.
PharmExec
AUGUST 18, 2023
Treatment indicated as the first and only for patients with fibrodysplasia ossificans progressiva.
Pharmacy Times
AUGUST 18, 2023
Opportunities for an additional specialization in molecular pathology may be helpful to train professionals in the real-time interpretation of gene therapy test results.
Pharmaceutical Commerce
AUGUST 18, 2023
Supporting health plan clinical preparation and financial modeling.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
246 
Let's personalize your content